Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was -0.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 8.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Ascentage Pharma Group International was 35.10% per year. The lowest was -176.60% per year. And the median was -0.40% per year.
Ascentage Pharma Group International (OTCPK:ASPHF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ascentage Pharma Group International 3-Year EPS without NRI Growth Rate Related Terms
ASPHF vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's 3-Year EPS without NRI Growth Rate falls into.
Ascentage Pharma Group International 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -0.40% mean?
Ascentage Pharma Group International (ASPHF) has a 3-Year EPS without NRI Growth Rate of -0.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ascentage Pharma Group International and its competitors. According to the industry distribution chart, Ascentage Pharma Group International ranks #819 out of 1160 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Ascentage Pharma Group International's 3-Year EPS without NRI Growth Rate too high?
Ascentage Pharma Group International's current 3-Year EPS without NRI Growth Rate is -0.40%. Based on the distribution chart, Ascentage Pharma Group International ranks #819 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascentage Pharma Group International has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #819 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Ascentage Pharma Group International in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current 3-Year EPS without NRI Growth Rate is -0.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $7.06, compared to a current price of $4.53 — trading 35.8% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -0.40%. Ascentage Pharma Group International's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current 3-Year EPS without NRI Growth Rate is -0.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 35.8% below its estimated GF Value™ of $7.06.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
3-Year EPS without NRI Growth Rate: -0.40%
GF Value™: $7.06 vs. price of $4.53 (35.8% below fair value)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
61GF Score
Get the complete analysis for ASPHF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
